scholarly journals EPV196/#377 Progesterone triggers carcinogenesis in a mouse model that phenocopies high grade serous carcinoma harboring a germline BRCA mutation

Author(s):  
C-H Cho ◽  
SY Kwon ◽  
S-J Shin ◽  
S Lee ◽  
J Kim
2019 ◽  
Vol 3 (4) ◽  
pp. 99-103
Author(s):  
Tarinee Manchana ◽  
Ruangsak Lertkhachonsuk ◽  
Chinachote Teerapakpinyo

Aim: To identify the frequency of somatic BRCA mutation in epithelial ovarian cancer (EOC), particularly those with high grade subtypes. Methods: Patients diagnosed with EOC included fallopian tube cancer or peritoneal cancer who had surgery during January 2015 to December 2016 were included. High grade subtypes included high grade serous carcinoma, poorly differentiated endometrioid carcinoma, and clear cell carcinoma. BRCA1 and BRCA2 mutations were tested using DNA extracted from formalin-fixed paraffin embedded block or a fresh tumor specimen then analyzed by next generation sequencing system. Patients who had no germline BRCA mutation in their peripheral blood DNA investigated by bi-directional Sanger sequencing were diagnosed as having somatic BRCA mutation.Results: 36 patients were enrolled; majority of the patients (33patients; 97.2%) had EOC, 1 patient (2.8%) had fallopian tube cancer and 2 patients (5.6%) had peritoneal cancer. 28 patients (77.8%) had high grade serous carcinoma, 6 (16.7%) had poorly differentiated endometrioid carcinoma, and 2 (5.6%) had clear cell carcinoma. BRCA1 mutation was detected in tumor tissues of 2 patients (5.6%). These two patients had high grade serous carcinoma and significant family history of breast and/or ovarian cancers. However, BRCA1 mutations were detected in the peripheral blood in both of them.Conclusion: Only 5.6% of BRCA1 mutation was detected in ovarian tumor tissues, all mutations were found in high grade serous subtype. However, BRCA mutations were detected in the peripheral blood in both of them. Germline BRCA mutation was diagnosed, thus there were no somatic mutations in this study.


Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3468
Author(s):  
Gulisa Turashvili ◽  
Conxi Lazaro ◽  
Shengjie Ying ◽  
George Charames ◽  
Andrew Wong ◽  
...  

Background: Approximately 25% of women diagnosed with tubo-ovarian high-grade serous carcinoma have germline deleterious mutations in BRCA1 or BRCA2, characteristic of hereditary breast and ovarian cancer syndrome, while somatic mutations have been detected in 3–7%. We set out to determine the BRCA mutation rates and optimal tissue requirements for tumor BRCA testing in patients diagnosed with tubo-ovarian high-grade serous carcinoma. Methods: Sequencing was performed using a multiplexed polymerase chain reaction-based approach on 291 tissue samples, with a minimum sequencing depth of 500X and an allele frequency of >5%. Results: There were 253 surgical samples (87%), 35 biopsies (12%) and 3 cytology cell blocks (1%). The initial failure rate was 9% (25/291), including 9 cases (3%) with insufficient tumor, and 16 (6%) with non-amplifiable DNA. Sequencing was successful in 78% (228/291) and deemed indeterminate due to failed exons or variants below the limit of detection in 13% (38/291). Repeat testing was successful in 67% (28/42) of retested samples, with an overall success rate of 86% (251/291). Clinically significant (pathogenic, likely pathogenic) variants were identified in 17% (48/276) of complete and indeterminate cases. Successful sequencing was dependent on sample type, tumor cellularity and size (p ≤ 0.001) but not on neoadjuvant chemotherapy or age of blocks (p > 0.05). Conclusions: Our study shows a 17% tumor BRCA mutation rate, with an overall success rate of 86%. Biopsy and cytology samples and post-chemotherapy specimens can be used for tumor BRCA testing, and optimal tumors measure ≥5 mm in size with at least 20% cellularity.


2020 ◽  
Author(s):  
Kevin W. McCool ◽  
Rork Kuick ◽  
Yali Zhai ◽  
Zach Freeman ◽  
Rong Wu ◽  
...  

2017 ◽  
Vol 9 (8) ◽  
pp. 519-531 ◽  
Author(s):  
Robert T. Neff ◽  
Leigha Senter ◽  
Ritu Salani

Ovarian cancer is a heterogeneous disease that encompasses a number of different cellular subtypes, the most common of which is high-grade serous ovarian cancer (HGSOC). Still today, ovarian cancer is primarily treated with chemotherapy and surgery. Recent advances in the hereditary understanding of this disease have shown a significant role for the BRCA gene. While only a minority of patients with HGSOC will have a germline BRCA mutation, many others may have tumor genetic aberrations within BRCA or other homologous recombination proteins. Genetic screening for these BRCA mutations has allowed improved preventative measures and therapeutic development. This review focuses on the understanding of BRCA mutations and their relationship with ovarian cancer development, as well as future therapeutic targets.


2014 ◽  
Vol 233 (3) ◽  
pp. 228-237 ◽  
Author(s):  
Cheryl A Sherman-Baust ◽  
Elisabetta Kuhn ◽  
Blanca L Valle ◽  
Ie-Ming Shih ◽  
Robert J Kurman ◽  
...  

2021 ◽  
Author(s):  
Maxence Wisztorski ◽  
Philippe Saudemont ◽  
Soulaimane Aboulouard ◽  
Tristan Cardon ◽  
Fabrice Narducci ◽  
...  

Abstract Background : BRCA 1 or 2 mutations have been known to be drivers of high-grade serous ovarian carcinomas (HGSC). As no efficient screening is currently available, a bilateral prophylactic salpingo-oophorectomy is the recommended procedure to avoid this often lethal carcinomas. However, a proportion of BRCA mutation carriers refuse to undergo this procedure due to significant impacts on quality and quantity of life, especially if a hormone replacement therapy is contra-indicated. Such decision expose them to developing a pelvic serous carcinoma. A better undersanding of high-grade serous cancer pathogenesis, rather stemming from fallopian tubes than from ovary itself, makes interesting a two-step prophylactic strategy in which tubes are removed as soon as possible, followed by oophorectomies at the time of menopause. Thus women are protected against HGSC with no immediate need of an HRT. Following this idea and considering the concept of junctional “hot spots “ (called mesothelo-müllerian junctions) for the development of HGSC, we suggested as first step to perform a bilateral prophylactic radical fimbriectomy rather than salpingectomy with a delayed oophorectomy (RF/DO). This operation was tested in a national phase 2 trial from 2011-2014 (NCT01608074). Radical Fimbriectomy (RF) consists of the surgical removal of both fallopian tubes along with a tiny part of the adherent ovary to suppress the tubal source of possible dysplastic cells from which can stem a high-grade invasive tumor, through stepwise cellular and genomic altereations ranging from p53 signatures to serous tubal intraepithelial carcoinoma (STIC), just before genuine invasive HGSC, through intermediate aspects (STIL) and (TILT). Methods : In this context, we carried out an in-depth proteomics analysis of these “pre-invasive ” epithelial lesions based on spatially resolved proteomic/ and bioinformatics systems biology platforms platform guided by immunohistochemistry (IHC) technique. Results : Specific markers related to each preneoplastic lesions and in particular from normal to p53 signatures were evaluated. We identified EIF3B, MOB1B and Emilin2, CAVIN1 as bad prognosis markers of P53 signature whereas CAVIN2, SPTANi, FBLN5 as good prognosis markers. Among the novel markers identified, mutated proteins as well as hidden proteins translated from alternative ORF Proteome have been sequenced and characterized. Conlusion : In summary, our results represent a novel pioneer approach to identify the unique under investigated markers that can characterize the molecular mechanism occurring in the preneoplastic lesion in fimbria at the origin of the HGSC.


2021 ◽  
pp. canres.0106.2021
Author(s):  
Lixing Chen ◽  
Yali Zhai ◽  
Yisheng Wang ◽  
Eric R. Fearon ◽  
Gabriel Núñez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document